Introduction {#s1}
============

Ultrasound (US) has been used for decades in differentiating benign and malignant lesions because of its low cost, ease of access, and non-invasiveness. For example, it belongs to the triad (physical examination, mammography and US), commonly used to assess the risk of breast cancer ([@B1]). Moreover, it can detect thyroid nodules as small as 2 mm in size and predicts malignancy based on features like irregular border, hypo-echogenicity, and calcification ([@B2], [@B3]). However, none of these features can individually predict malignancy and conventional US alone has shown moderate accuracy in detecting malignant lesions ([@B4]). Therefore, improvements to US technique have been sought.

The introduction of contrast agents (contrast-enhanced US/CEUS) allows for visibility of blood flow within the lesion, which improves its characterization ([@B5]). The current in-use contrast media are second-generation agents as SonoVue. These agents remain within the intravascular space, which increases their safety and allows for continuous imaging over the enhancement period ([@B6]). Several studies have reported high sensitivity and specificity for CEUS in differentiating malignant lesions with the breast, thyroid, liver and kidneys ([@B5], [@B7]--[@B9]). A recent meta-analysis showed no significant difference between CEUS and contrast-enhanced computed tomography (CECT) and magnetic resonance imaging (CEMRI) in terms of the diagnostic accuracy in characterizing focal liver lesions (FLLs) ([@B8]).

Shear wave elastography (SWE) relies on the degree of lesion stiffness when subjected to external pressure. Malignant nodules have harder consistency (less elasticity) than benign ones due to the uncontrolled proliferation of cancer cells ([@B10]). Therefore, SWE has been investigated for differentiating benign and malignant nodules. Compared to conventional US, SWE is more quantitative and is less operator-dependent, allowing more effective detection of malignant tumors ([@B11]). Recent diagnostic test accuracy (DTA) studies and meta-analyses showed high sensitivity and specificity for SWE in detecting malignant lesions within the breast and hepatic tissues ([@B11]--[@B13]).

According to our knowledge, data are lacking on the direct comparison between CEUS and SWE; therefore, we performed a meta-analysis to evaluate the diagnostic accuracy of CEUS and SWE in differentiating malignant tumors in the breast, liver, thyroid, kidneys, and prostate tissues in comparison to histopathology as a reference test. Moreover, we used network meta-analysis (NMA) to compare the diagnostic accuracy of both tests in malignant tumor differentiation.

Materials and Methods {#s2}
=====================

This meta-analysis has been conducted and reported in accordance with the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (The PRISMA-DTA Statement) ([@B14]); [Supplementary File I](#SM1){ref-type="supplementary-material"}.

Literature Search
-----------------

We searched Medline (via PubMed), Embase, SCOPUS and Web of Science for diagnostic accuracy studies that evaluated the use of CEUS and SWE in the differentiation of malignant tumors in different body organs. The following search terms were used with different combinations in different databases: Contrast-enhanced Ultrasound OR CEUS OR Ultrasound OR SonoVue OR Shear Wave Elastography OR SWE OR Sonoelastography OR Elastosonography AND Malignant OR Cancer OR Tumor OR Benign OR Adenoma OR Adenocarcinoma OR Carcinoma OR Nodule. No search filters of any sort were used during the search. All retrieved search results from database search (including bibliographic data and abstracts) were imported into EndNote (X7) for duplicate removal and then were transferred to a Microsoft Excel Sheet for screening.

Study Screening
---------------

For a study to be eligible for inclusion, it must have matched all the following criteria: (1) Population: Patients, suspected or diagnosed with malignancy in any body organ, (2) Intervention: CEUS or SWE \[no specifications by US system or probe type\], (3) Comparator: Histopathology, (4) Outcomes: Sensitivity, specificity, positive predictive value \[PPV\], and negative predictive value \[NPV\], and (5) Study type: Diagnostic accuracy study. Two independent authors reviewed the title and abstract of retrieved records against our eligibility criteria and classified them into: eligible, non-eligible, or requires further screening (seems to fit the inclusion criteria, but further confirmation is required). The full-text articles of the latter type were retrieved and underwent a second wave of screening. Any discrepancy between the two reviewers\' decisions was solved by a senior reviewer (with a 15-year experience in secondary analysis and evidence synthesis methods) after reviewing the debated studies in reference to the pre-specified PICO criteria.

Data Extraction and Quality Assessment
--------------------------------------

An extraction sheet (in Microsoft Excel) was formatted and pilot-tested before final extraction. The sheet was customized to extract the baseline data of the imaging device, enrolled patients, as well as the raw diagnostic data of each included study. For pilot testing, two reviewers extracted these data from 5 included studies and the datasets were matched and compared with the original studies by a third reviewer. Each set of data was extracted by two reviewers and discordant decisions were resolved by discussion. These discussions included re-examining the studies, inspecting their available additional data sources and re-evaluating the former decisions. When the discrepancies remained, a senior reviewer examined the studies and settled the differences. The extracted data included (I) baseline characteristics of enrolled participants, (II) study design, (III) diagnostic test parameters: Parameters, cutoff value and US system for SWE and contrast agent, US technique, probe and mechanical index for CEUS, and (IV) Outcome data: true positive (TP), true negative (TN), false positive (FP), and false negative (FN) values. When these values were not directly given, they were calculated from the processed data as sensitivity, specificity, PPV, and NPV, using the statistical calculator on RevMan software (Version 5.3 for Windows). We used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) score to assess the quality of included studies. It consists of 14 (yes/no/unclear) questions to assess different forms of bias within DTA studies ([@B15]).

Data Analysis
-------------

Pairwise meta-analyses were done under the random-effects model when two or more studies investigated the same predefined research question with the same laboratory test. We extracted the sensitivity, specificity, positive likelihood ratio (LR), negative LR, and diagnostic odds ratio (DOR) values for CEUS and SWE compared to histopathology as a reference standard. The DOR is calculated as (TP X TN)/ (FP X FN) and defined as the odds of having a positive test result in a patient with disease compared with the odds of a positive test result in a patient without disease. Moreover, summary receiver operating characteristic (SROC) curves were constructed to examine diagnostic accuracy. All statistics were reported as absolute values with their 95% confidence interval (95% CI). A *p*-value \< 0.05 was considered statistically significant. The Chi-square and I-square statistics were calculated in order to assess heterogeneity. Significant heterogeneity was considered to be present if the chi-square *p*-value was \< 0.1 (as per the Cochrane Handbook for Systematic Reviews of Intervention). Data were presented into five subgroups according to cancer site: breast, liver, thyroid, kidneys, and prostate. Network meta-analyses were conducted to compare the diagnostic accuracy of CEUS vs. SWE in malignancy detection. Heterogeneity and inconsistency were checked by the I^2^ and the corresponding *p*-value. All statistical analyses were conducted on MetaDiSc (version 1.4) and R software (version 3.4.3).

Results {#s3}
=======

Literature Search and Study Characteristics
-------------------------------------------

Database search retrieved 5896 unique citations. Following title and abstract screening, 422 full-text articles were retrieved for further scrutiny. Finally, 114 diagnostic accuracy studies (65 on SWE and 50 on CEUS; one study by 4 assessed both modalities), reporting data from 15926 patients (5680 for CEUS and 10392 for SWE) were included in our network meta-analysis ([Figure 1](#F1){ref-type="fig"}, Bibliographic details in [Supplementary File II](#SM2){ref-type="supplementary-material"}). According to the QUADAS score, 25 (21.5%), 30 (25.8%), 22 (18.9%), 23 (19.8%), and 16 (13.8%) studies scored 10, 11, 12, 13, and 14, respectively. The baseline data of enrolled participants, as well as the characteristics of the used US systems for SWE and CEUS tests are illustrated in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, respectively.

![PRISMA flow diagram of literature search and study selection.](fonc-09-00102-g0001){#F1}

###### 

Baseline characteristics of enrolled patients and criteria of the used SWE system.

  **References**                    **Country**   **Study design**       **Patients/Lesions (N)**                                                **Age (Years)**              **Male: Female**   **Organ**   **Condition**                                     **Reference test/Gold standard**                   **SWE parameters**                         **Cutoff value (Kpa)**   **US system**
  --------------------------------- ------------- ---------------------- ----------------------------------------------------------------------- ---------------------------- ------------------ ----------- ------------------------------------------------- -------------------------------------------------- ------------------------------------------ ------------------------ -----------------------------------------------------------
  Li et al. ([@B16])                China         Prospective cohort     276 (296 lesions)                                                       45.4 ± 14.7                  100% F             Breast      Benign vs. malignant breast masses                Histopathology                                     SWS                                        4.39 m/sec               S3000 US scanner (Siemens)
  Yang et al. ([@B17], [@B18])      China         Retrospective cohort   218 (225 lesions)                                                       45.3 ± 14.6                  100% F             Breast      Benign vs. malignant breast masses                Histopathology                                     Emean                                      36.1 Kpa                 Aplio500 US machine (Toshiba)
  Elmoneam et al. ([@B13])          Egypt         Prospective cohort     63 (63 lesions)                                                         34.7 ± 5.9                   100% F             Breast      Benign vs. malignant breast masses                Histopathology                                     Emax                                       106.55 Kpa               N/A
  Kim et al. ([@B19])               Korea         Retrospective cohort   171 (177 lesions)                                                       45.17 ± 9.37                 100% F             Breast      Small breast lesions \< 2 cm                      Histopathology                                     Emax                                       87.5 Kpa                 Aixplorer system (Supersonic Imagine
  Youk et al. ([@B20])              Korea         Prospective cohort     123 (130 lesions)                                                       46.7 ± 11.2                  100% F             Breast      Breast cancer                                     Histopathology                                     Emean                                      82.2 Kpa                 Aixplorer ultrasound system
  Tang et al. ([@B21])              China         Prospective cohort     98 (133 lesion)                                                         N/A                          100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Mean SWV                                   3.68 m/s                 Siemens S3000 US scanner
  Choi et al. ([@B22])              Korea         Retrospective cohort   54 (56 lesions)                                                         40.76 + 68.07                100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Emean                                      44.3 Kpa                 Aixplorer US system (SuperSonic Imagine
  Liu et al. ([@B12])               China         Prospective cohort     130 (139 lesions)                                                       44.74 ± 14.77                100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Max SWV                                    5.37 m/s                 Siemens Acuson S3000 ultra-sound machine
  Golatta et al. ([@B23])           Germany       Prospective cohort     103 (104 lesions)                                                       51 ± 18.56                   100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Mean SWV                                   5.18 m/s                 Siemens Medical Solutions
  Youk et al. ([@B24])              Korea         Retrospective cohort   324 (389 lesions)                                                       46.0 ± 11.4                  100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Eratio                                     5.14                     Aixplorer US system (SuperSonic Imagine
  Ko et al. ([@B25])                Korea         Retrospective cohort   33 (34 lesions)                                                         46.4 ± 7.5                   100% F             Breast      Breast Non-mass lesions                           Histopathology                                     Emean                                      41.6 Kpa                 Aixplorer US system (SuperSonic Imagine
  Lee et al. ([@B26])               Korea         Prospective cohort     134 (144 lesions)                                                       49.1 ± 12.8                  100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Emax                                       147.2 Kpa                Aixplorer US system (SuperSonic Imagine
  Ng et al. ([@B27])                Malaysia      Prospective cohort     152 (159 lesions)                                                       52 + 20.5                    100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Emax                                       56.0 Kpa                 Aixplorer ultrasound system (SuperSonic Imagine
  Tian et al. ([@B28])              China         Retrospective cohort   210 (210 lesions)                                                       43.12 ± 13.34                100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Emax                                       80.8 Kpa                 Aixplorer ultrasound system (SuperSonic Imagine
  Olgun et al. ([@B29])             Turkey        Prospective cohort     109 (115 lesions)                                                       51 + 17.5                    0.02:1             Breast      Benign vs. malignant breast lesion                Histopathology                                     Eratio                                     4.7                      Aixplorer ultrasound system (SuperSonic Imagine
  Chang et al. ([@B30])             Korea         Prospective cohort     115 (133 lesions)                                                       51.4 + 11.75                 100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Emean                                      60.7 Kpa                 IU-22 (Phillips) OR HDI 5000 sonography unit
  Yao et al. ([@B31])               China         Prospective cohort     206 (206 lesions)                                                       44.6 + 13.3                  100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Mean SWV                                   4.22 m/s                 Acuson S2000 ultrasound system (Siemens
  Lee et al. ([@B26])               Korea         Retrospective cohort   139 (156 lesions)                                                       43.54 ± 9.94                 100% F             Breast      Solid breast masses                               Histopathology                                     Emax                                       82.3 Kpa                 Aixplorer ultrasound system (SuperSonic Imagine
  Seo et al. ([@B32])               Korea         Prospective cohort     37 (45 lesions)                                                         47.4 +14.75                  100% F             Breast      Benign vs. malignant breast lesion                Histopathology                                     Emean                                      67.8 Kpa                 Aplio 500; Toshiba
  Au et al. ([@B33])                Canada        Prospective cohort     112 (123 lesions)                                                       49.2+10.7                    100% F             Breast      Solid breast masses                               Histopathology                                     Eratio                                     3.56                     Aixplorer Multiwave V3, Supersonic Imagine
  Chang et al. ([@B34])             Korea         Prospective cohort     129 (150 lesions)                                                       47.8+8.83                    100% F             Breast      Benign vs. malignant solid breast lesions         Histopathology                                     Emean                                      80 Kpa                   Aixplorer, SuperSonic Imagine
  Choi et al. ([@B35])              Korea         Retrospective cohort   113 (116 lesions)                                                       48.4+10                      100% F             Breast      Breast non-mass lesions                           Histopathology                                     Emean                                      85.1 Kpa                 Aixplorer, SuperSonic Imagine
  Chung et al. ([@B36])             Korea         Retrospective cohort   71 (79 lesions)                                                         48+10.67                     100% F             Breast      Breast papillary lesions                          Histopathology                                     Emax                                       62.1 Kpa                 Aixplorer, SuperSonic Imagine
  Choi et al. ([@B22])              Korea         Retrospective cohort   199 (205 lesions)                                                       51.7 ± 13.3                  100% F             Breast      Benign vs. malignant solid breast lesions         Histopathology                                     Emean                                      85.8 Kpa                 Aixplorer, SuperSonic Imagine
  Dobruch-Sobczak et al. ([@B37])   Poland        Retrospective cohort   76 (84 lesions)                                                         59.9+13                      100% F             Breast      Focal breast lesions                              Histopathology                                     Eav.adj.                                   68.5 Kpa                 Aixplorer, SuperSonic Imagine
  Guo et al. ([@B38])               China         Prospective cohort     379 (404 lesions)                                                       N/A                          100% F             Breast      Focal breast lesions                              Histopathology                                     SWS                                        3.015 m/s                Siemens ACUSON S2000
  Hong et al. ([@B39])              Korea         Prospective cohort     218 (264 lesions)                                                       46.4+10.5                    100% F             Breast      Solid breast masses                               Histopathology                                     Emax                                       44.1 Kpa                 N/A
  Kim et al. ([@B40])               China         Retrospective cohort   67 (67 lesions)                                                         41.5+2.29                    100% F             Breast      Fibroadenoma vs. phylloids tumor                  Histopathology                                     Emean                                      43.9 Kpa                 Aixplorer, SuperSonic Imagine
  Klotz et al. ([@B41])             France        Retrospective cohort   142 (167 lesions)                                                       57.7 +11                     100% F             Breast      Benign vs. malignant solid breast lesions         Histopathology                                     Emax                                       106 Kpa                  Aixplorer, SuperSonic Imagine
  Lee et al. ([@B42])               Korea         Retrospective cohort   139 (140 lesions)                                                       45.5 + 10.33                 100% F             Breast      Complex cystic and solid breast lesions           Histopathology                                     Emax                                       108.5 Kpa                Aixplorer, SuperSonic Imagine
  Li et al. ([@B16])                China         Retrospective cohort   116 (116 lesions)                                                       48.56+ 14.4                  100% F             Breast      Breast lesions BIRADS IV                          Histopathology                                     SWS                                        3.49 m/s                 Siemens S3000 US machine
  Shi et al. ([@B43])               China         Prospective cohort     251 (279 lesions)                                                       45.3 6 11.8                  100% F             Breast      Benign vs. malignant solid breast lesions         Histopathology                                     SD                                         8.05 Kpa                 Aixplorer, SuperSonic Imagine
  Sim et al. ([@B44])               UK            Retrospective cohort   52 (52 lesions)                                                         67                           100% F             Breast      IDC                                               Histopathology                                     Emean                                      50 Kpa                   Aixplorer, SuperSonic Imagine
  Sim et al. ([@B44])               UK            Retrospective cohort   52 (52 lesions)                                                         67                           100% F             Breast      ILC                                               Histopathology                                     Emean                                      50 Kpa                   Aixplorer, SuperSonic Imagine
  Wu et al. ([@B45])                China         Retrospective cohort   192 (209 lesions)                                                       N/A                          100% F             Breast      Benign vs. malignant solid breast lesions         Histopathology                                     N/A                                        N/A                      Siemens ACUSON S2000
  Youk et al. ([@B20])              Korea         Retrospective          78 (79 lesions)                                                         45.5 + 11.6                  100% F             Breast      Benign vs. malignant solid breast lesions         Histopathology                                     Eratio                                     3.7                      Aixplorer, SuperSonic Imagine
  Zhang et al. ([@B46])             China         Prospective cohort     97 (98 lesions)                                                         44.74 ± 14.77                100% F             Breast      Small breast lesions \< 10 cm                     Histopathology                                     SWV                                        3.27 m/s                 Siemens ACUSON S2000
  Cong et al. ([@B47])              China         Prospective cohort     315 (326 lesions)                                                       44.51 + 11.81                100% F             Breast      Breast masses                                     Histopathology                                     SD                                         13.75                    Aixplorer, SuperSonic Imagine
  Park et al. ([@B48], [@B49])      Korea         Retrospective cohort   133 (156 lesions)                                                       47.8 ± 12.7                  100% F             Breast      Palpable breast masses                            Histopathology or periodic imaging surveillance    Emax                                       45.1 Kpa                 Aixplorer, SuperSonic Imagine
  Wang et al. ([@B50])              China         Retrospective cohort   63 (67 lesions)                                                         40.1 + 21.2                  100% F             Breast      Non-mass breast lesions                           Histopathology                                     Emax                                       81.07 Kpa                iU22 Philips
  Kasai et al. ([@B51])             Japan         Prospective cohort     273 patients with chronic liver disease                                 59.64 ± 14.40 70.98 ± 9.33   1:01               Liver       HCC                                               Histopathology                                     Young\'s Modulus                           N/A                      Aixplorer US system (SuperSonic Imagine S.A.)
  Gerber et al. ([@B52])            Germany       Prospective cohort     106 (106 lesions)                                                       55.5+16.74                   3.8:1              Liver       Characterization of solid HFLs                    Histopathology and CE imaging for benign lesions   Emedian                                    37.6 Kpa                 Aixplorer ultrasound system (SuperSonic Imagine)
  Özmen et al. ([@B53])             Turkey        Prospective cohort     20 (20 lesions)                                                         4.74+4                       2.3:1              Liver       Heamangioma vs. malignant liver lesions           Histopathology                                     Emean                                      23.62 Kpa                Aixplorer ultrasound system (SuperSonic Imagine)
  Tian et al. ([@B54])              China         Prospective cohort     221 (229 lesions)                                                       48.9 + 13.2                  2.4:1              Liver       Benign vs. malignant HFLs                         Histopathology                                     Emax                                       39.6 Kpa                 Aixplorer, SuperSonic Imagine
  Ahmad et al. ([@B55])             UK            Prospective cohort     50 (11 with PSA\> 20)                                                   69                           100% M             Prostate    Prostate cancer                                   Histopathology                                     Shear wave velocity and Young\'s modulus   N/A                      SuperSonic Imagine
  Boehm et al. ([@B56])             Germany       Prospective cohort     60 patients with suspected prostate cancer                              N/A                          100% M             Prostate    Prostate cancer                                   histopathology                                     Young\'s Modulus                           50 Kpa                   TRUS Aixplorer
  Porsch et al. ([@B57])            Germany       Prospective cohort     69 (794 samples)                                                        65+8                         100% M             Prostate    Prostate cancer                                   Histopathology                                     Young\'s Modulus                           48 Kpa                   SuperSonic Imagine Ultrasound System AIXPLORER
  Woo et al. ([@B58])               Korea         Prospective cohort     87 (87 lesions)                                                         66 ± 9.0                     100% M             Prostate    Prostate cancer                                   Histopathology                                     Young\'s Modulus                           43.9 Kpa                 SuperSonic Imagine
  Correas et al. ([@B59])           France        Prospective cohort     184 (1040 samples)                                                      65.1 6 7.6                   100% M             Prostate    Prostate cancer                                   Histopathology                                     Young\'s Modulus                           35 Kpa                   SuperSonic Imagine
  Glybochko et al. ([@B60])         Russia        Prospective cohort     302 (134 with suspected PC, 120 with confirmed PC and 48 healthy men)   N/A                          100% M             Prostate    Prostate cancer                                   Histopathology                                     Young\'s Modulus                           50 Kpa                   Super Sonic Imagine
  Zhang et al. ([@B61], [@B62])     China         Prospective cohort     59 (71 lesions)                                                         50.5 ± 9.1                   0.4:1              Thyroid     Benign vs. malignant thyroid nodules \< 10 mm     Histopathology                                     Shear wave velocity                        2.910 m/s                Acuson S2000 Seimens VTTQ
  Azizi et al. ([@B63])             USA           Prospective cohort     676 (707 lesions)                                                       51.2+15                      0.2:1              Thyroid     Thyroid cancer                                    Histopathology                                     Shear wave velocity                        3.54 m/s                 Virtual Touch IQ Software on the Siemens ACU-SON S3000 US
  Liu et al. ([@B12])               China         Prospective cohort     271 (331 lesions)                                                       45.9 ± 13.4                  0.3:2              Thyroid     Malignant thyroid nodule                          Histopathology                                     SWE mean                                   39.3 Kpa                 SuperSonic Imagine
  Wang et al. ([@B64])              China         Prospective cohort     322 (322 nodules)                                                       50.5 ± 12.6                  0.3:1              Thyroid     Malignant thyroid nodule                          Histopathology                                     Elastic modulous and SWS                   3.52 m/s                 Aplio500, Toshiba Medical Systems
  Duan et al. ([@B65])              China         Prospective cohort     118 (137 lesions)                                                       45.9 ± 13.4                  0.6:1              Thyroid     Malignant thyroid nodule                          Histopathology                                     SWE mean                                   34.5                     Aixplorer; Supersonic Imagine
  Liu et al. ([@B66])               China         Prospective cohort     238 (254 lesions)                                                       50.9 ± 11.9                  0.3:1              Thyroid     Malignant thyroid nodule                          Histopathology                                     SWS                                        2.78 m/s                 N/A
  Liu et al. ([@B67])               China         Retrospective cohort   227 (313 lesions)                                                       46.14 ± 9.70                 0.2:1              Thyroid     Malignant thyroid nodule                          Histopathology                                     Emax                                       51.95 Kpa                N/A
  Kim et al. ([@B68])               Korea         Retrospective cohort   99 (99 lesions)                                                         45.7+13                      N/A                Thyroid     Malignant thyroid nodule                          Histopathology                                     Emean                                      62 Kpa                   Aixplorer US system (SuperSonic Imagine)
  Deng et al. ([@B69])              China         Prospective cohort     146 (175 nodules)                                                       46.36 ± 12.5                 0.4:1              Thyroid     Malignant thyroid nodule                          Histopathology                                     SWS                                        2.59 m/s.                Siemens Acuson S2000 US machine
  Baig et al. ([@B70])              China         Prospective cohort     122 (163 nodules)                                                       53 ± 13.7                    0.2:1              Thyroid     Malignant thyroid nodule                          Histopathology                                     Emax                                       67.3 Kpa                 Aixplorer, Supersonic Imagine
  Dobruch-Sobczak et al. ([@B71])   Poland        Prospective cohort     119 (169 lesions)                                                       49.2+14                      0.3:1              Thyroid     Characterization of thyroid nodules               Histopathology                                     Emean                                      30.5 Kpa                 Aixplorer, SuperSonic Imagine
  Liu et al. ([@B72])               China         Prospective cohort     49 (64 lesions)                                                         45.3 ± 13.1                  0.4:1              Thyroid     benign vs. malignant solid Thyroid lesions        Histopathology                                     Emean                                      38.3 Kpa                 Q-box TM; Super Sonic Imagine
  Park et al. ([@B73])              Korea         Retrospective cohort   453 (476 nodules)                                                       45.7+10.33                   0.2:1              Thyroid     Benign vs. malignant solid Thyroid lesions        Histopathology                                     Emean                                      85.2 Kpa                 Aixplorer, SuperSonic Imagine
  Samir et al. ([@B74])             USA           Prospective cohort     35 (35 lesions)                                                         55 + 16.1                    0.5:1              Thyroid     Benign vs. malignant thyroid follicular lesions   Histopathology                                     Young\'s Modulus                           22.3 Kpa                 Aixplorer, SuperSonic Imagine
  Yang et al. ([@B75])              China         Prospective cohort     107 (107 lesions)                                                       54.0 ± 9.4                   0.26:1             Thyroid     Benign vs. malignant solid Thyroid lesions        Histopathology                                     Mean SWS                                   3.01 m/s                 Acuson S3000 (Siemens)
  Zhou et al. ([@B76])              China         Prospective cohort     290 (302 lesions)                                                       49.80+12.34                  0.4:1              Thyroid     Benign vs. malignant solid Thyroid lesions        Histopathology                                     Mean SWS                                   2.6 m/s                  Acuson S3000 (Siemens)

###### 

Baseline characteristics of enrolled patients and criteria of the used CEUS system.

  **References**                 **Country**   **Study design**     **Organ**   **Condition**                                                 **Patients/ Lesions (N)**   **Age (Years)**   **Male: Female**   **Contrast agent**        **Reference test**                                   **US technique**                                                            **Mechanical index**                        **Probe**
  ------------------------------ ------------- -------------------- ----------- ------------------------------------------------------------- --------------------------- ----------------- ------------------ ------------------------- ---------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------------
  Bertolotto et al. ([@B5])      Italy         Retrospective        Kidney      Indeterminate renal masses with equivocal enhancement on CT   47 (30 HP)                  65 ± 13           4.75:1             2.4 mL SonoVue            Histopathology                                       Pulse inversion harmonic imaging Cadence contrast pulse sequencing          0.05--0.21                                  Convex array (C5--1) & (4C1) &(C5--2 HDI) & (CA430E)
  Cai et al. ([@B77])            China         Prospective cohort   Kidney      Benign vs. malignant renal masses                             73 (73 lesions)             56.36 ± 12.2      1.6:1              1.0--1.8 mL SonoVue       Histopathology and follow up data                    Acuson Sequoia 512, Siemens,                                                0.21--0.23                                  4C1-S convex probe 1--4 MHz
  Chang et al. ([@B30])          USA           Prospective cohort   Kidney      Renal solid and cystic lesions                                44 (23 HP lesions)          56 ± 14           0.7:1              Sonazoid                  Histopathology and follow up data                    Siemens Acuson Sequoia 512                                                  0.19                                        4C1 abdominal transducer
  Chen et al. ([@B78], [@B79])   China         Prospective cohort   Kidney      RCC vs. AML                                                   99 (102 lesions)            56.6 ± 16.5       2:01               1.2 ml of SonoVue         Histopathology                                       Acuson S2000 (contrast pulse sequencing)                                    N/A                                         N/A
  Chen et al. ([@B80])           China         Prospective cohort   Kidney      Complex cystic renal masses                                   59 (71 lesions)             49.6 + 14.25      2.9:1              2.4 mL of SonoVue         Histopathology and follow up data                    Coded phase inversion harmonic imaging (Logiq 9 scanner GE Healthcare)      0.07--0.10                                  3.5C (2.5--5.0 MHz) and 4C (1.0--4.0 MHz) convex transducers
  Defortescu et al. ([@B81])     France        Prospective cohort   Kidney      Complex renal cysts                                           47 (47 lesions)             46 + 9.75         1.8:1              1.2 mL SonoVue            Histopathology and follow up data                    ACUSON S2000-Siemens−10                                                     0.06--0.1                                   Convex probe 3--4.5 mHz
  Li et al. ([@B16])             China         Retrospective        Kidney      RCC vs. AML                                                   411 (429 lesions)           54.12 ± 12.57     1.9:1              1.2 mL SonoVue            Histopathology                                       E9 system (GE Healthcare                                                    0.11                                        C1-5, 1--5 MHz
  Li et al. ([@B82])             China         Retrospective        Kidney      Solid Renal Masses                                            91 (100 lesions)            62.0 ± 15.6       2.6:1              1.0--1.2 ml SonoVue       Histopathology                                       Acuson Sequoia 512 scanner                                                  \< 0.2                                      4V1 vector transducer, 1--4 MHz
  Lu et al. ([@B83])             China         Retrospective        Kidney      RCC vs. AML                                                   189 (189 lesions)           47.3 ± 20.7       1.6:1              1.2 ml SonoVue            Histopathology                                       LOGIC E9                                                                    \< 0.1                                      C1--5, 1.5 MHz
  Nicolau et al. ([@B84])        Spain         Prospective cohort   Kidney      Indeterminate renal masses by CT                              72 (83 nodules)             64.9 + 14.5       1.9:1              2.4 mL of SonoVue         Histopathology and follow up data                    Cadence contrast pulse sequencing technology (CPS)                          \< 0.2 at Sequoia 512, \< 0.009 at S2000)   4C1 convex array probe
  Oh et al. ([@B85])             Korea         Retrospective        Kidney      RCC vs. AML (small masses)                                    49 lesions                  61+11.5           2.5:1              SonoVue                   Histopathology                                       N/A                                                                         N/A                                         N/A
  Sanz et al. ([@B86])           Spain         Prospective cohort   Kidney      Complex cystic renal masses                                   66 (67 lesions)             67.8+ 1.83        2.7:1              2.4 mL SonoVue            Histopathology                                       Hitachi Preirus                                                             N/A                                         EUP-C715 probe (5--1 MHz
  Tamas-Szora et al. ([@B87])    Romania       Prospective cohort   Kidney      RCC                                                           32 (33 lesions)             60.9 ± 10.43      1:01               1.6 mL of SonoVue         Histopathology                                       General Electric Logiq 7 system                                             0.09--0.11                                  Convex wide-band transducer (2--5.5 MHz)
  Tian et al. ([@B28])           China         Prospective cohort   Kidney      Renal SOL                                                     367 (378 lesions)           N/A               N/A                1.2 mL SonoVue            Histopathology                                       ACUSON S2000 Ultrasound System                                                                                          Probe 4C1, 2.5--5 MHz
  Wei et al. ([@B88])            China         Retrospective        Kidney      Benign vs. malignant solid renal masses                       118 (118 lesions)           53.5 ± 12.6       1.6:1              1.6--2.4 mL SonoVue       Histopathology                                       Contrast pulse sequence, Sequoia 512 ultrasound system (Siemens             0.18−0.20                                   4C1, 3--4 MHz
  Yong et al. ([@B89])           Singapore     Retrospective        Kidney      Undetermined renal masses                                     63 (74 nodules)             62.4 ± 14.5       1.6:1              1.5 ml of SonoVue         Histopathology                                       Aplio 500, Toshiba Medical Systems AND iU22, Philips Healthcare             N/A                                         N/A
  Zhang et al. ([@B90])          China         Prospective cohort   Kidney      Benign vs. malignant thyroid nodules                          148 (157 lesions)           45.4 ± 10.5       N/A                2.4 ml SonoVue            Histopathology                                       Contrast pulse sequence (CPS) imaging. Acuson, Sequoia 512 Encompass        0.20--0.23                                  15L8w probe (8--14 MHz)
  Miyamoto et al. ([@B91])       Japan         Prospective cohort   Breast      Focal breast lesions                                          127 (127 lesions)           48.5 ± 12.3       :1                 0.015 mL/kg Sonazoid      Histopathology                                       AplioXG, Toshiba AND, Hitachi-Aloka AND Logiq E9, GE                        0.1--0.4                                    Broadband linear phased-array transducer
  Xia et al. ([@B92])            China         Retrospective        Breast      Papillary breast lesions                                      50 (52 lesions)             51 +13.57         :1                 2.4 mL SonoVue            Histopathology                                       Pulse-inverse harmonic imaging technique \[Philips iU22\]                   0.05--0.08                                  3--9-MHz linear transducer
  Xiao et al. ([@B93])           China         Prospective cohort   Breast      Subcentimetric breast lesions                                 203 (209 lesions)           47+15.25          :1                 4.8 mL of SonoVue         Histopathology                                       Pulse inversion harmonic technique w iU22 (Philips)                         0.06                                        9--3-MHz linear transducer
  Yuan et al. ([@B94])           China         Prospective cohort   Breast      Breast tumors                                                 216 (216 lesions)           46 ± 12           :1                 2.5 mL SonoVue            Histopathology                                       Sequoia; Siemens Medical Solutions                                          N/A                                         10 MHz transducer
  Aubé et al. ([@B95])           France        Prospective cohort   Liver       Diagnosis of HCC (\< 3 cm)                                    381 (544 lesions)           62 ± 9.69         4.6:1              SonoVue                   Histopathology, CT and MRI according to EASL-AASLD   N/A                                                                         N/A                                         N/A
  Beyer et al. ([@B96])          Germany       Retrospective        Liver       Benign vs. malignant liver nodules                            83 (83 lesions)             59.8 +10          2.6:1              1--2.4 ml SonoVue         Histopathology                                       LOGIQ E9, GE                                                                N/A                                         1--6 MHz curved probe
  Corvino et al. ([@B97])        Italy         Prospective cohort   Liver       Cystic and cyst like liver lesions                            48 (50 lesions)             65+15             0.9:1              2.4 or 4.8 mL SonoVue     Histopathology                                       MyLab 70 Twice scanner (Esaote)                                             N/A                                         D multifrequency (2.5--5 MHz) convex probes
  Feng et al. ([@B98])           China         Retrospective        Liver       HCC differentiation                                           271 (374 lesions)           49.25 + 17        3.9:1.0            2.4 mL SonoVue            Histopathology                                       iU22 system (Philips)                                                       \< 0.1                                      (5--2 MHz) convex transducer (C5-2).
  Iwamoto et al. ([@B99])        Japan         Retrospective        Liver       Macroscopic HCC                                               77 (79 lesions)             70 ± 9            2.7:1              0.015 ml/kg Sonazoid      Histopathology                                       (tissue harmonic grayscale imaging) LOGIQ 7 or E9 US                        0.2--0.3                                    Convex or linear probes with a frequency of 2--5 or 4--9 MHz
  Kobayashi et al. ([@B100])     Japan         Retrospective        Liver       NS-HCC                                                        85 (85 lesions)             66 + 13.75        2.9:1              0.015 ml/kg Sonazoid      Histopathology                                       Wide-band pulse-inversion harmonic imaging (HI VISION Ascendus (Hitachi))   0.16--0.2                                   Microconvex probe (EUP- C715, 3.5 MHz
  Kobayashi et al. ([@B101])     Japan         Retrospective        Liver       Liver metastasis                                              98 (148 lesions)            66.46 ± 11.2      1.7:1              0.0075 mL/kg Sonazoid     Histopathology                                       SSA 770 A or 790 A US system (Toshiba)                                      0.17--0.27                                  3.75-MHz convex probe
  Liu et al. ([@B12])            China         Prospective cohort   Liver       Hyperechoic HFL                                               102 (135 lesions)           51.4 ± 12.5       2.8:1              1.5 mL of SonoVue         Histopathology                                       GE Logiq9 color Doppler ultrasonography                                     0.11                                        convex array probe (frequency: 3.5--5 MHz)
  Quaia et al. ([@B102])         Italy         Retrospective        Liver       Benign vs. malignant liver lesions in cirrhotic patients      46 (55 lesions)             55 ± 10           0.8:1              2.4 mL SonoVue            Histopathology                                       Sequoia, Acuson-Siemens AND iU22 (iU22; Philip)                             0.09--0.14                                  Convex array 2--4 MHz 4C1 transducer AND 2--5-MHz broadband curvilinear probe
  Sandrose et al. ([@B103])      USA           Retrospective        Liver       CT undetermined HFL                                           78 (163 lesions)            61.8 + 15.25      1.1:1              1.2 ml bolus of SonoVue   Histopathology and PET/CT follow up                  Pulse inversion harmonic imaging (GE LOGIQ 9E)                              N/A                                         N/A
  Schellhaas et al. ([@B104])    Germany       Prospective cohort   Liver       HCC by CEUS and ESCULAP                                       100 (100 lesions)           66.1 + 7.17       5.7:1              1.5 ml SonoVue            Histology and imaging                                GE Logiq E9 AND Siemens Acuson S2000 AND Toshiba Aplio 500                  N/A                                         N/A
  Tada et al. ([@B105])          Japan         Prospective cohort   Liver       Macroscopic HCC                                               99 (99 lesions)             67.8 ± 10.4       2.7:1              0.015 ml/kg of Sonazoid   Histopathology                                       Wideband harmonic imaging (Aplio XG system, Toshiba)                        (0.18--0.28)                                5-MHz convex transducer 1.4 and 5.3 MHz
  Thakur et al. ([@B106])        India         Prospective cohort   Liver       HCC                                                           50 (50 lesions)             52 + 14.25        1.4:1              2.4 ml SonoVue            Histopathology, CT and MRI                           Xario XG (Toshiba)                                                          \< 0.2                                      
  Wang et al. ([@B64])           Germany       Prospective cohort   Liver       Superficial HFL                                               27 (27 lesions)             N/A               2.4:1              2.4 ml SonoVue            Histopathology, one patient by MRI                   Philips iU22, LOGIQ E9, Aplio 500                                           N/A                                         High frequency transducer (7.5--12 MHz)
  Wu et al. ([@B107])            China         Prospective cohort   Liver       Focal hepatic lesions                                         46 (55 lesions)             46.5 + 15.2       1.2:1              2.4-mL dose of SonoVue    Histopathology, CECT and MRI                         Philips iU22 US system                                                      0.06                                        5C2 multi- frequency convex probe
  Yin et al. ([@B108])           China         Prospective cohort   Liver       Cholangiocarcinoma vs. inflammatory lesions                   40 (40 lesions)             58.7 + 9.701      1.4:1              1.5 mL of SonoVue         Histopathology                                       LOGIQ E9 (GE Healthcare)                                                    \< 0.1                                      C5-1, 2.0--4.0 MHz
  Zhang et al. ([@B109])         China         Prospective cohort   Liver       Benign vs. malignant liver lesions                            156 (176 lesions)           50.7 + 16.25      1.9:1              2.4 mL of SonoVue         Histopathology                                       Acuson S2000 ultrasound system Seimens                                      N/A                                         4C1 convex array probe; frequency 2.0--4.0 MHz
  Takahashi et al. ([@B110])     Japan         Prospective cohort   Liver       HFL \< 30 mm                                                  56 (67 lesions)             65.8 ± 10.1       2.5:1              0.0075 mL/kg Sonazoid     Histopathology                                       SSA-790A ultrasound system (Aplio                                           (0.20--0.25)                                3.75 MHz convex probe
  Taimr et al. ([@B111])         Canada        Prospective cohort   Liver       Liver metastasis                                              89 (89 lesions)             31--87            1.6:1              1.5--2.4 mL SonoVue       Histopathology                                       Contrast-tuned imaging Hitachi 900 and Hitachi Preirus                      N/A                                         2.5--5.0 MHz probe
  Cantisani et al. ([@B9])       Italy         Prospective cohort   Thyroid     Thyroid nodules                                               48 (53 lesions)             49.4 + 8.75       2.7:1              4.8 mL SonoVue            Histopathology                                       MyLab 70XvG, Esaote                                                         N/A                                         Linear probe (7--12 MHz) (N:36)
  Deng et al. ([@B69])           China         Prospective cohort   Thyroid     Malignant thyroid nodule                                      146 (175 nodules)           46.36 ± 12.5      0.4:1              2.4 mL of the SonoVue     Histopathology                                       Siemens Acuson S2000 US machine                                             0.1                                         9L4, 5.0 MHz to 14.0 MHz
  Diao et al. ([@B112])          China         Prospective cohort   Thyroid     Benign vs. malignant thyroid nodules                          77 (87 lesions)             52.4 ± 17.2       N/A                1.5 mL SonoVue            Histopathology                                       Siemens Acuson S2000 US                                                     0.06--0.1                                   5- to 14-MHz linear array transducer (9L4)
  Giusti et al. ([@B113])        Italy         Prospective cohort   Thyroid     Benign vs. malignant thyroid nodules                          63 (HP in 38 lesions)       55.9 ± 14.7       0.2:1              4.8 ml of SonoVue         Histopathology                                       MyLab 70 US scanner                                                         N/A                                         7.5-MHz linear probe
  Jiang et al. ([@B114])         China         Prospective cohort   Thyroid     Benign vs. malignant calcified thyroid nodules                122 (122 nodules)           46 + 12           0.4:1              2.4 mL of the SonoVue     Histopathology                                       Contrast pulse sequencing (CPS) (ACUSON Sequoia 512 (Siemens Healthcare)    0.32                                        15L8w high- frequency linear transducer
  Wu et al. ([@B107])            China         Retrospective        Thyroid     Benign vs. malignant thyroid nodules                          133 lesions                 46.3 + 10         0.5:1              1.2 mL SonoVue            Histopathology                                       ESAOTE MyLab 90 X-vision                                                    0.05--0.07)                                 L522 (3--9 MHz) linear-array probe
  Zhang et al. ([@B46])          China         Prospective cohort   Thyroid     Benign vs. malignant thyroid nodules                          70 (200 lesions)            49.6 + 12.8       0.3:1              2.0 mL SonoVue            Histopathology                                       Acuson S2000                                                                \< 0.10                                     9-MHztransducer
  Zhang et al. ([@B90])          China         Prospective cohort   Thyroid     Benign vs. malignant thyroid nodules                          246 (319 patients)          46.1 ± 15.2       0.5:1              2.4 ml SonoVue            Histopathology                                       Contrast pulsed sequencing (CPS) Siemens Acuson S2000                       N/A                                         9 L4 transducer
  Zhang et al. ([@B90])          China         Prospective cohort   Thyroid     Benign vs. malignant thyroid nodules                          111 (145 nodules)           48 + 13.45        0.2:1              1.6 mL SonoVue            Histopathology                                       Contrast tuned imaging Mylab Twice Esaote                                   N/A                                         LA522 transducer (3--9 MHz)
  Zhou et al. ([@B115])          China         Prospective cohort   Thyroid     Benign vs. malignant thyroid nodules                          161 (167 lesions)           44.14 + 12.01     0.4:1              2.4 ml SonoVue            Histopathology                                       DC-8EXP; Mindray                                                            0.15                                        L12-3E transducer

Outcomes of Pair-Wise Meta-Analysis
-----------------------------------

### Breast Cancer

Detailed figures for pairwise meta-analysis in all five organs are illustrated in [Supplementary File III](#SM3){ref-type="supplementary-material"}. The pooled sensitivity, specificity, positive LR, and negative LR for CEUS in detection of breast malignant lesions were 0.89 (95% CI, 0.85, 0.92), 0.85 (95% CI, 0.81, 0.89), 6.13 (95% CI, 4.70, 8.01), and 0.12 (95% CI, 0.07, 0.21), respectively. The pooled DOR was 49.66 (95% CI, 29.42, 83.82) and the area under the receiving-operating characteristic (AUROC) curve was 0.92, [Figure 2A](#F2){ref-type="fig"}. No heterogeneity was observed for sensitivity (*p* = 0.15) or specificity (*p* = 0.95).

![Summary receiver operating characteristic curve of **(A)** Contrast Enhanced Ultrasound, and **(B)** Shear Weight Elastography in breast cancer diagnosis.](fonc-09-00102-g0002){#F2}

For SWE, the pooled sensitivity, specificity, positive LR, and negative LR were 0.84 (95% CI, 0.83, 0.86), 0.86 (95% CI, 0.85, 0.87), 7.12 (95% CI, 5.54, 9.15), and 0.18 (95% CI, 0.15, 0.22), respectively. The pooled DOR was 46.22 (95% CI, 31.33, 68.18) with an AUROC of 0.93, [Figure 2B](#F2){ref-type="fig"}. Significant heterogeneity was observed for sensitivity (*p* \< 0.0001) and specificity (*p* \< 0.0001).

### Hepatic Cancer

The pooled sensitivity, specificity, positive LR, and negative LR for CEUS in differentiating malignant hepatic lesions were 0.78 (95% CI, 0.76, 0.81), 0.89 (95% CI, 0.87, 0.91), 6.51 (95% CI, 3.90, 10.85), and 0.13 (95% CI, 0.06, 0.25), respectively. The overall DOR was 57.94 (95% CI, 24.78, 135.45) with an AUROC of 0.95, [Figure 3A](#F3){ref-type="fig"}. The included studies were heterogeneous in the estimates of sensitivity (*p* \< 0.0001) and specificity (*p* \< 0.0001).

![receiver operating characteristic curve of **(A)** Contrast Enhanced Ultrasound, and **(B)** Shear Weight Elastography in hepatic cancer diagnosis.](fonc-09-00102-g0003){#F3}

For SWE, the pooled sensitivity, specificity, positive LR, and negative LR were 0.82 (95% CI, 0.77, 0.87), 0.83 (95% CI, 0.76, 0.89), 4.30 (95% CI, 2.85, 6.48), and 0.29 (95% CI, 0.12, 0.71), respectively. The overall DOR was 14.46 (95% CI, 4.09, 51.04) with an AUROC of 0.90, [Figure 3B](#F3){ref-type="fig"}. The included studies were heterogeneous in the estimates of sensitivity (*p* \< 0.0009) and specificity (*p* \< 0.0001).

### Thyroid Cancer

The pooled sensitivity, specificity, positive LR, and negative LR for CEUS in detecting malignant thyroid nodules were 0.81 (95% CI, 0.78, 0.84), 0.88 (95% CI, 0.86, 0.90), 6.01 (95% CI, 3.88, 9.31), and 0.23 (95% CI, 0.17, 0.31), respectively. The overall DOR was 28.54 (95% CI, 16.79, 48.51) with an AUROC of 0.91, [Figure 4A](#F4){ref-type="fig"}. Significant heterogeneity was observed for sensitivity (*p* = 0.001) and for specificity (*p* \< 0.0001).

![Summary receiver operating characteristic curve of **(A)** Contrast Enhanced Ultrasound, and **(B)** Shear Weight Elastography in thyroid cancer diagnosis.](fonc-09-00102-g0004){#F4}

For SWE, the pooled sensitivity, specificity, positive LR, and negative LR were 0.67 (95% CI, 0.64, 0.69), 0.77 (95% CI, 0.76, 0.79), 3.50 (95% CI, 2.93, 4.18), and 0.33 (95% CI, 0.25, 0.45), respectively. The overall DOR was 11.17 (95% CI, 8.04, 15.51) with an AUROC of 0.84, [Figure 4B](#F4){ref-type="fig"}. Significant heterogeneity was observed for sensitivity (*p* \< 0.0001) and specificity (*p* \< 0.0001).

### Renal Cancer

The sensitivity of CEUS ranged from 0.71 to 0.98 with a pooled sensitivity of 0.87 (95% CI, 0.85, 0.88). Specificity ranged from 0.50 to 0.97 with a pooled specificity of 0.84 (95% CI, 0.82, 0.87). The pooled positive and negative LRs were 5.55 (95% CI, 3.74, 8.22) and 0.12 (95% CI, 0.07, 0.19), respectively. The overall DOR was 53.44 (95% CI, 29.89, 95.56) with an AUROC of 0.95, [Figure 5A](#F5){ref-type="fig"}. Significant heterogeneity was observed for sensitivity (*p* \< 0.0001) and specificity (*p* \< 0.0001).

![Summary receiver operating characteristic curve of **(A)** Contrast Enhanced Ultrasound in renal cancer diagnosis, and **(B)** Shear Weight Elastography in prostate cancer diagnosis.](fonc-09-00102-g0005){#F5}

### Prostate Cancer

The sensitivity of SWE ranged from 0.42 to 0.96 with a pooled sensitivity of 84% (95% CI, 0.80, 0.87). Specificity ranged from 0.70 to 0.95 with a pooled specificity of 0.84 (95% CI, 0.82, 0.86). The pooled positive and negative LRs were 4.59 (95% CI, 2.68, 7.87) and 0.18 (95% CI, 0.07, 0.44), respectively. The overall DOR was 25.35 (95% CI, 7.15, 89.89) with an AUROC of 0.89 ([Figure 5A](#F5){ref-type="fig"}). Significant heterogeneity was observed for sensitivity (*p* \< 0.0001) and specificity (*p* \< 0.0001) ([Figure 5B](#F5){ref-type="fig"}). [Table 3](#T3){ref-type="table"} summarizes the diagnostic results for both tests in different cancer sites.

###### 

Summary of the results of pooled sensitivity, specificity, positive, and negative likelihood ratios for SWE and CEUS in different cancers.

  **Cancer**        **Test**   **Sensitivity**             **Specificity**             **+ ve LR**                  **-ve LR**                  **DOR**                         **AUROC**
  ----------------- ---------- --------------------------- --------------------------- ---------------------------- --------------------------- ------------------------------- -----------
  Breast cancer     SWE        0.84 (95% CI, 0.83, 0.86)   0.86 (95% CI, 0.85, 0.87)   7.12 (95% CI, 5.54, 9.15)    0.18 (95% CI, 0.15, 0.22)   46.22 (95% CI, 31.33, 68.18)    0.93
                    CEUS       0.89 (95% CI, 0.85, 0.92)   0.85 (95% CI, 0.81, 0.89)   6.13 (95% CI, 4.70, 8.01)    0.12 (95% CI, 0.07, 0.21)   49.66 (95% CI, 29.42, 83.82)    0.92
  Hepatic cancer    SWE        0.82 (95% CI, 0.77, 0.87)   0.83 (95% CI, 0.76, 0.89)   4.30 (95% CI, 2.85, 6.48)    0.29 (95% CI, 0.12, 0.71)   14.46 (95% CI, 4.09, 51.04)     0.90
                    CEUS       0.78 (95% CI, 0.76, 0.81)   0.89 (95% CI, 0.87, 0.91)   6.51 (95% CI, 3.90, 10.85)   0.13 (95% CI, 0.06, 0.25)   57.94 (95% CI, 24.78, 135.45)   0.95
  Thyroid cancer    SWE        0.67 (95% CI, 0.64, 0.69)   0.77 (95% CI, 0.76, 0.79)   3.50 (95% CI, 2.93, 4.18)    0.33 (95% CI, 0.25, 0.45)   11.17 (95% CI, 8.04, 15.51)     0.84
                    CEUS       0.81 (95% CI, 0.78, 0.84)   0.88 (95% CI, 0.86, 0.90)   6.01 (95% CI, 3.88, 9.31)    0.23 (95% CI, 0.17, 0.31)   28.54 (95% CI, 16.79, 48.51)    0.91
  Renal carcinoma   CEUS       0.87 (95% CI, 0.85, 0.88)   0.84 (95% CI, 0.82, 0.87)   5.55 (95% CI, 3.74, 8.22)    0.12 (95% CI, 0.07, 0.19)   53.44 (95% CI, 29.89, 95.56)    0.95
  Prostate cancer   SWE        84% (95% CI, 0.80, 0.87)    0.84 (95% CI, 0.82, 0.86)   4.59 (95% CI, 2.68, 7.87)    0.18 (95% CI, 0.07, 0.44)   25.35 (95% CI, 7.15, 89.89)     0.89

*AUROC, Area under the receiving-operating curve; CEUS, contrast-enhanced ultrasound; DOR, Diagnostic odds ratio; LR, Likelihood ratio; SWE, Shear wave elastography*.

Outcomes of Network Meta-Analysis
---------------------------------

Corresponding network plots and forest plots of network meta-analysis between CEUS and SWE are shown in [Figure 6](#F6){ref-type="fig"}. In breast cancer, NMA showed that CEUS was associated with significantly higher DOR than SWE (DOR = 27.14, 95% CI \[2.30, 51.97\], *p* = 0.011). While NMA showed no significant difference between CEUS and SWE in detecting hepatic (DOR = −6.67, 95% CI \[-15.08, 1.74, *p* = 0.61\]) and thyroid malignant lesions (DOR = 3.79, 95% CI \[−3.10, 10.68\], *p* = 0.58). No significant heterogeneity or inconsistency were observed between the pooled studies for breast (*I*^2^ = 10%, *p* = 0.30) and hepatic cancer (*I*^2^ = 20%, *p* = 0.21). While a *p*-value of 0.05 indicated significant heterogeneity among the studies of thyroid cancer; therefore, the random-effects model was employed.

![Network plots showing direct evidence between Contrast Enhanced Ultrasound and Shear Weight Elastography in **(A)** breast cancer, **(B)** hepatic caner, and **(C)** thyroid cancer. Also, forest plots of network meta-analysis between Contrast Enhanced Ultrasound and Shear Weight Elastography vs. histopathology in **(A)** breast cancer, **(B)** hepatic caner, and **(C)** thyroid cancer. **(D)** Forest plot CEUS vs. SWE of breast cancer. **(E)** Forest plot CEUS vs. SWE of hepatic cancer. **(F)** Forest plot CEUS vs. SWE of thyroid cancer.](fonc-09-00102-g0006){#F6}

Ranking Diagnostic Tests
------------------------

According to Glas et al. ([@B116]), the DOR is considered as an indicator of ranking of competing diagnostic tests. According to our results, CEUS achieved the highest DOR in detecting breast and thyroid malignant lesions, while SWE achieved the highest DOR in detecting hepatic malignant lesions.

Discussion {#s4}
==========

This meta-analysis of DTA studies provides a comprehensive assessment and comparison of the diagnostic accuracy of two US modalities in differentiating malignant tumors in different body organs. It showed relatively high sensitivity (between 78 and 89%) and specificity (between 84 and 89%) for CEUS in identifying malignant lesions in the breast, liver, thyroid and kidneys. Moreover, it demonstrated relatively high sensitivity (between 82 and 84%) and specificity (between 83 and 86%) for SWE in differentiating malignant tumors within the breast, liver and prostate. However, it had relatively lower sensitivity (67%) and specificity (77%) in identifying malignant nodules within the thyroid gland.

Our results support some recent practice guidelines that endorse the use of CEUS and SWE in differentiating malignant lesions within the liver and the breast ([@B117], [@B118]). Moreover, it provides new data on a comparison that can impact the clinical practice. Through NMA, we compared the diagnostic accuracy of CEUS and SWE in three organs (where data on both tests were available in the literature). Our network and ranking analysis showed that CEUS was more accurate than SWE in differentiating breast and thyroid lesions (although the difference was not significant in thyroid malignancy according to NMA). On the other hand, SWE ranked higher in terms of diagnostic accuracy in differentiating hepatic malignant lesions (although the difference was not significant according to NMA).

Our results are in agreement with a former meta-analysis by Sadigh et al. that showed high sensitivity and specificity for SWE in differentiating breast malignant lesions \[88 and 83% in comparison to 84 and 86% in our analysis; ([@B11])\]. However, our sensitivity and specificity results are quite lower than those obtained by Liu et al. in a meta-analysis on SWE accuracy in differentiating thyroid malignancy \[sensitivity 81% and specificity 84%; ([@B12])\]. Likewise, another meta-analysis reported high sensitivity and specificity (93 and 90%, respectively) for CEUS in identifying hepatic malignant lesions ([@B119]). The observed discrepancy between our findings and those of the aforementioned meta-analyses may be attributed to the different sample size (being larger in our analysis) or the lesional characteristics of enrolled patients (being easier to identify in the studies included in the other meta-analysis i.e., less depth and clear contrast from the surrounding tissue).

Interestingly, a meta-analysis by Guang et al. showed comparable diagnostic accuracy for SonoVue-enhanced US with contrast-enhanced computed tomography and magnetic resonance imaging ([@B8]). Moreover, CEUS has other advantages over these modalities as ease of access, lack of radiation exposure or nephrotoxic materials; limitations that affect the use of CT and MRI in several diagnostic applications ([@B120], [@B121]). It is also fair to recognize that both tests have limitations as well. For example, SWE suffers from operator-dependency and manual compression, while the adverse effects of the contrast agent is a concern with CEUS use. Further technical improvements with both modalities would further enhance their clinical potential.

Strength Points
---------------

This NMA directly compares the diagnostic accuracies of CEUS and SWE in different cancer sites and using different analytic approaches as pairwise, network and ranking pooled analyses. Therefore, it provides a holistic evaluation of the comparison of both techniques in different body organs. We performed a thorough literature search and retrieved a large number of studies (relatively large sample size), which adds to the validity and generalizability of our findings. Unlike former reviews that retrieved a small number of studies and focused on one test in one organ, we aimed to provide a comprehensive assessment of both tests in different organs and a high quality comparison whenever suitable data were provided.

Limitations and Future Research Implications
--------------------------------------------

Our meta-analysis has some limitations. First, the observed heterogeneity in the majority of our outcomes may be due to differences in study design and patient characteristics. Second, we could not examine the effects of lesion characteristics, such as size and depth on the diagnostic accuracy of both tests due to lack of data. Third, many of the included studies did not mention whether the results of CEUS or SWE were interpreted with blinding to the findings of histopathology or not. Future studies should report diagnostic accuracy data based on the size and depth of the lesions to allow more detailed analysis. Moreover, they should adhere to the Standards for Reporting of Diagnostic Accuracy "STRAD" checklist in reporting their methods and findings to allow a more thorough critical appraisal.

Conclusion {#s5}
==========

Both diagnostic tests (CEUS and SWE) showed relatively high sensitivity and specificity in detecting malignant tumors in different organs; CEUS had higher diagnostic accuracy than SWE in detecting breast and thyroid cancer, while SWE had higher accuracy in detecting hepatic cancer (the differences in the latter two cancer types were not statistically significant). These results endorse the use of both tests for malignancy detection and rank their accuracy in different organs. Future studies should provide more data to allow characterization of both tests in lesions of different size or depth.
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